Purple Biotech (PPBT)
(Delayed Data from NSDQ)
$0.50 USD
0.00 (0.42%)
Updated May 16, 2024 03:59 PM ET
After-Market: $0.51 +0.01 (1.57%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PPBT 0.50 0.00(0.42%)
Will PPBT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PPBT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PPBT
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher
PPBT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PPBT
12 Health Care Stocks Moving In Friday's After-Market Session
Purple Biotech Advances in Oncology Drug Development
Buy Rating Affirmed on Purple Biotech’s CM24 Favorable Interim Phase 2 Results in PDAC Treatment
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Purple Biotech’s Cancer Study Shows Promise